SILO

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Retrieved on: 
Tuesday, November 21, 2023
Research, Patient safety, Nose, SILO, Brain, Anxiety, PTSD, Post-traumatic stress disorder, Nasal cavity, Silicon, Therapy, Area studies, Argyreia nervosa, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Key Points: 
  • “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
  • Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia.
  • The drug dispersion through the nose to brain has been designed to optimize patient safety and therapeutic delivery.

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Therapy, PTSD, Toxicity, GLP, SILO, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range.
  • In collaboration with AmplifyBio, Silo Pharma’s contract research organization (CRO) partner, the six- to eight-week non-good laboratory practice (GLP) study will include single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study.
  • “Determining the dose range that should be studied is an important step before taking a new drug candidate into a first-in-human trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Retrieved on: 
Monday, October 16, 2023
RA, MS, Tendon, B cell, Central nervous system, Therapy, University, Joint, UMB, Rheumatoid arthritis, SILO, Multiple sclerosis, DSM-IV codes, CNS, University of Maryland, College Park, Medical imaging, Fine chemical

ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).

Key Points: 
  • SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
  • “The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects.
  • In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated.

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, October 11, 2023
Post-traumatic stress disorder, Therapy, PTSD, Biomarker, SILO, Plasma protein binding, Anxiety, Columbia University, Stress-related disorders, Research, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.
  • “The human factors study is an important step as we prepare and plan to enter the clinic with SPC-15 for the treatment of PTSD and stress-related disorders,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University pursuant to a sponsored research agreement and option.

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Retrieved on: 
Wednesday, September 20, 2023
Columbia University, Therapy, Anxiety, Drug discovery, Biopharmaceutical, Disorder, Stress-related disorders, FDA, SILO, IND, Pharmacology, PTSD, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA). SPC-15 is a targeted intranasal prophylactic intended for the treatment and prevention of anxiety, PTSD, and other stress-related disorders. 

Key Points: 
  • SPC-15 is a targeted intranasal prophylactic intended for the treatment and prevention of anxiety, PTSD, and other stress-related disorders.
  • “Our pre-clinical data indicate that SPC-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels.
  • In conjunction with Columbia University, we are pleased to announce this milestone in advancing our potential therapeutic development for those suffering from stress-induced anxiety and PTSD.
  • A pre-IND meeting request for collaborative discussions with the FDA will be filed early 2024
    SPC-15 utilizes metabolic biomarker profiling to treat anxiety, PTSD, and other stress-related disorders.

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Retrieved on: 
Tuesday, September 12, 2023
Columbia University, Anxiety, Drug discovery, FDA, Therapy, Research, SILO, IND, Biomarker, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the initiation of an exploratory feasibility study evaluating a selected delivery mechanism for its intranasal therapeutic drug SPC-15. The Company’s collaboration partner for the study is a developer and manufacturer of innovative drug delivery systems and technology.

Key Points: 
  • SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University
    ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the initiation of an exploratory feasibility study evaluating a selected delivery mechanism for its intranasal therapeutic drug SPC-15.
  • The Company’s collaboration partner for the study is a developer and manufacturer of innovative drug delivery systems and technology.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “We believe our research partner’s patented proprietary nasal-to-brain technology could be well suited for the delivery of SPC-15, and we expect to receive the results of these in vitro lab tests by the end of September.
  • Its core technology is patent-protected.

Silo Wellness Announces LOI to Acquire NUGL/Kaya in a Transaction Valued at CAD $43,289,624.60; CSE to Halt Trading Until Shareholder Approval

Retrieved on: 
Tuesday, August 29, 2023
OTC Markets Group, Treasury, Finder, Letter, CSE, Canadian Securities Exchange, CAD, FSE, USD, Silo, Acquisition, Transaction, SILO, Sales, Security (finance), Bank

SILO will acquire 100% of the issued and outstanding shares of NUGL in exchange for 2,010,000,000 shares from treasury (all shares herein are pre-consolidation), for a purchase price of CAD $40,200,000.00.

Key Points: 
  • SILO will acquire 100% of the issued and outstanding shares of NUGL in exchange for 2,010,000,000 shares from treasury (all shares herein are pre-consolidation), for a purchase price of CAD $40,200,000.00.
  • NUGL stock options, warrants, and other convertible securities will be adjusted to receive SILO Common Shares on an economically equivalent basis.
  • The final structure of the Transaction is subject to receipt of final tax, corporate, and securities law advice and securities regulatory and CSE approval for both SILO and NUGL.
  • The combined market cap of the two companies at the CAD $0.02/share valuation would be CAD $43,289,624.60.

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Retrieved on: 
Thursday, August 10, 2023
Columbia University, San Francisco, Patent, Intellectual property, Clarivate, Drug development, Psychopathology, Therapy, Central nervous system, University, Anxiety, University of California, San Francisco, Composition, Research, Biomarker, IP, CNS, History of the University of Maryland, College Park, Pain, Dementia, Investigational New Drug, Acquisition, FDA, United States patent law, Information services, SILO, IND, Alzheimer's disease, PTSD, Peptide, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™, a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development.

Key Points: 
  • Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development.
  • Silo Pharma engages in the acquisition, licensing, and development of intellectual property and technology rights from leading universities and researchers, including the use of psychedelic drugs.
  • “Our new agreement with Clarivate gives us the opportunity to step up our intellectual property and patent expansion efforts and reinforce protection for our novel assets under development,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • In 2023, year-to-date, Silo Pharma has been awarded 3 new patents and one patent extension:
    U.S. Patent 16/825,371, covering SPU-21 as a method of selectively targeting inflamed synovial tissue.

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

Retrieved on: 
Tuesday, August 8, 2023
Columbia University, Patent, Therapy, Anxiety, Efficacy, Research, Disorder, Drug discovery, United States patent law, SILO, PTSD, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in SPC-15’s novel protocol intended for treatment and prevention of anxiety, PTSD, and other stress related disorders. The formulation development was in accordance with the Company’s sponsored research agreement and option with Columbia University. Linearity, accuracy, and repeatability were achieved in the feasibility study.

Key Points: 
  • The liquid nasal formulation will be used in SPC-15’s novel protocol intended for treatment and prevention of anxiety, PTSD, and other stress related disorders.
  • The formulation development was in accordance with the Company’s sponsored research agreement and option with Columbia University.
  • “The progress of our feasibility study investigating dose strengths of SPC-15 is a significant advancement in our development work with this pipeline candidate,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “Results of the feasibility study will determine our selection of the manufacturing processes, and we are currently in discussions with potential delivery partners.

Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Retrieved on: 
Wednesday, June 21, 2023
Patent, Nanoparticle, RA, University, Therapy, History of the University of Maryland, College Park, Peptide, Autoimmune disease, Joint, United States patent law, SILO, Diagnosis, Treatment, Rheumatoid arthritis, Fine chemical

SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model.

Key Points: 
  • SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis.
  • The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psilocybin as a therapeutic agent for rheumatoid arthritis (RA), our initial indication.”
    An estimated 1.3 million U.S. adults suffer from RA, the most common autoimmune disease in U.S.
  • The U.S. market for RA drugs is expected to generate $63 billion by 2027.1